Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study

Chemotherapy. 2016;61(6):281-6. doi: 10.1159/000445045. Epub 2016 Apr 13.

Abstract

Background: Several studies evaluating the prognostic factors of gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs) have been published. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been accepted as prognostic factors for cancer patients.

Materials and methods: This study included 132 patients diagnosed with GEP-NETs. Peripheral blood samples were collected before the pretreatment period.

Results: NLR and PLR were increased as the grade increased in NETs. The embryonic origin analysis revealed higher NLR and PLR rates in NETs of foregut origin. NLR and PLR were also higher in pancreatic NET patients compared to the gastroenteric NET patients. Analysis of NETs by TNM indicated that an advanced stage was accompanied by significantly higher NLR and PLR. We found a strong negative correlation between progression-free survival and NLR and PLR.

Conclusion: The study verified that NLR and PLR are simple laboratory findings that can be used to identify NETs with a worse outcome.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Area Under Curve
  • Blood Cell Count
  • Blood Platelets / cytology*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphocytes / cytology*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neuroendocrine Tumors / blood*
  • Neuroendocrine Tumors / diagnosis
  • Neutrophils / cytology*
  • Prognosis
  • ROC Curve
  • Sex Factors